Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control ...
Stocktwits on MSN
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback
Capricor’s peer-reviewed publication in Biomedicines reinforced the scientific foundation of its Duchenne therapy Deramiocel, ...
Capricor Therapeutics (CAPR) announced the publication in Biomedicines, an international peer-reviewed journal, describing a novel in-vitro ...
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the ...
Capricor Therapeutics finds itself navigating turbulent waters as a federal securities class action lawsuit casts uncertainty over the company's future. The legal investigation, made public on October ...
Eli Lilly has tapped former US Food and Drug Administration (FDA) biologics lead, Peter Marks, as its new head of infectious disease and senior VP of molecule discovery. Marks' hiring comes six months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback